Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto

The financial coverage granted by law in Chile for patients with psoriatic arthritis who require biological treatment is of paramount importance and a great advance. However physicians must be knowledgeable about the advantages and limitations of this therapy. The challenge of clinicians is to choos...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Ibáñez,Sebastián, Valenzuela,Francisca, Valenzuela,Omar
Lenguaje:	Spanish / Castilian
Publicado:	Sociedad Médica de Santiago 2020
Materias:	Arthritis, Psoriatic Biological Therapy Spondylitis, Ankylosing
Acceso en línea:	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000500657
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:scielo:S0034-98872020000500657
record_format	dspace
spelling	oai:scielo:S0034-988720200005006572020-09-29Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte SotoIbáñez,SebastiánValenzuela,FranciscaValenzuela,Omar Arthritis, Psoriatic Biological Therapy Spondylitis, Ankylosing The financial coverage granted by law in Chile for patients with psoriatic arthritis who require biological treatment is of paramount importance and a great advance. However physicians must be knowledgeable about the advantages and limitations of this therapy. The challenge of clinicians is to choose the drug with the greater odds of achieving therapeutic success, with less adverse events and lower costs for our health system. This article aims to help doctors to select the best biological treatment for a specific patient, trying to optimize its effectiveness, minimizing adverse effects, always looking for an efficient use of resources.info:eu-repo/semantics/openAccessSociedad Médica de SantiagoRevista médica de Chile v.148 n.5 20202020-05-01text/htmlhttp://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000500657es10.4067/S0034-98872020000500657
institution	Scielo Chile
collection	Scielo Chile
language	Spanish / Castilian
topic	Arthritis, Psoriatic Biological Therapy Spondylitis, Ankylosing
spellingShingle	Arthritis, Psoriatic Biological Therapy Spondylitis, Ankylosing Ibáñez,Sebastián Valenzuela,Francisca Valenzuela,Omar Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto
description	The financial coverage granted by law in Chile for patients with psoriatic arthritis who require biological treatment is of paramount importance and a great advance. However physicians must be knowledgeable about the advantages and limitations of this therapy. The challenge of clinicians is to choose the drug with the greater odds of achieving therapeutic success, with less adverse events and lower costs for our health system. This article aims to help doctors to select the best biological treatment for a specific patient, trying to optimize its effectiveness, minimizing adverse effects, always looking for an efficient use of resources.
author	Ibáñez,Sebastián Valenzuela,Francisca Valenzuela,Omar
author_facet	Ibáñez,Sebastián Valenzuela,Francisca Valenzuela,Omar
author_sort	Ibáñez,Sebastián
title	Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto
title_short	Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto
title_full	Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto
title_fullStr	Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto
title_full_unstemmed	Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto
title_sort	artritis psoriásica: la elección del fármaco antirreumático biológico en la ley ricarte soto
publisher	Sociedad Médica de Santiago
publishDate	2020
url	http://www.scielo.cl/scielo.php?script=sci_arttext&pid=S0034-98872020000500657
work_keys_str_mv	AT ibanezsebastian artritispsoriasicalaelecciondelfarmacoantirreumaticobiologicoenlaleyricartesoto AT valenzuelafrancisca artritispsoriasicalaelecciondelfarmacoantirreumaticobiologicoenlaleyricartesoto AT valenzuelaomar artritispsoriasicalaelecciondelfarmacoantirreumaticobiologicoenlaleyricartesoto
_version_	1718437127183663104

Artritis psoriásica: La elección del fármaco antirreumático biológico en la Ley Ricarte Soto

Ejemplares similares